MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-19-2024
Renalytix AI plc Revenue 2011-2026 | RNLX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Renalytix AI plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.29 M | 3.4 M | 2.97 M | 1.49 M | -63 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.4 M | -63 K | 2.02 M |
Quarterly Revenue Renalytix AI plc
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 522 K | - | 535 K | 709 K | 459 K | - | 724 K | 1.19 M | 969 K | - | 812 K | 845 K | - | - | 619 K | 400 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.19 M | 400 K | 708 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.82 | - | $ 950 M |  USA |
 |
Agilent Technologies
A
|
6.32 B | $ 114.84 | - | $ 34.9 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 168.22 | - | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 24.73 | - | $ 687 M | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 192.12 | - | $ 137 B | USA |
 |
DexCom
DXCM
|
4.66 B | $ 63.21 | - | $ 24.7 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
982 M | $ 89.66 | - | $ 11.2 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 109.62 | - | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 1.97 | - | $ 8.72 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 127.74 | - | $ 20.3 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 274.46 | - | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 75.89 | - | $ 5.12 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 16.3 | - | $ 175 M |  China |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 496.0 | - | $ 14.3 B | USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.67 | - | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 8.02 | - | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
895 M | $ 9.56 | - | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.33 | - | $ 388 M | USA |
 |
Natera
NTRA
|
820 M | $ 204.87 | - | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.42 | - | $ 426 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
24 M | $ 25.98 | 2.28 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 6.58 | - | $ 390 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 14.87 | - | $ 4.22 B | USA |
 |
Soleno Therapeutics
SLNO
|
190 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
149 M | $ 1.76 | - | $ 116 M | USA |
|
Biodesix
BDSX
|
71.3 M | $ 15.36 | - | $ 1.99 B | USA |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 488.19 | - | $ 184 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 27.2 | -0.04 % | $ 20 B |  Niderland |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.62 | - | $ 61.9 M | Irlanda |
 |
VolitionRx Limited
VNRX
|
1.73 M | $ 0.17 | - | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
932 M | $ 304.09 | - | $ 18.1 B | USA |
 |
Exagen
XGN
|
66.6 M | $ 3.08 | - | $ 66.4 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.15 | - | $ 6.26 M | USA |